QHSLab, Inc.

QHSLab sells a digital screening platform to small primary care practices, helping them spot and manage behavioral health issues like depression and anxiety between office visits. The company earns recurring per-patient, per-month subscription fees from participating practices, supplemented by sales of its AllergiEnd-branded in-office allergy skin testing kits and training. QHSLab targets independent physician-led practices with one to ten providers, deliberately avoiding large hospital systems, and competes against better-funded digital health and chronic care management vendors.

• Customer concentration: targets small independent primary care practices (1-10 providers); revenue depends entirely on practices billing payers correctly under evolving reimbursement rules.
• Reimbursement dependency: revenue tied to practices successfully billing Medicare/commercial payers for digital assessments and care management—any payer rule changes directly impair the model.
• No IP moat: company explicitly declines to pursue patent/trademark enforcement, relying only on trade secrecy while competing against better-resourced digital health and EHR vendors.